Forbion Capital Partners Raises €190m for New Investments

Final close of FCF I Co-Invest Fund and FCF II

NAARDEN, The Netherlands & MUNICH, Germany--(BUSINESS WIRE)-- Forbion Capital Partners, a leading investment firm dedicated to the life science sector, today announces the final closings of both FCF I Co-Invest Fund and of FCF II, raising a total of more than €190m ($240m). Forbion’s €54m Co-Invest Fund aims to invest alongside FCF I in a select number of late-stage FCF I portfolio companies. FCF II has an investment strategy similar to its predecessor fund FCF I. Forbion aims to invest the majority of the fund in Europe and the remainder in North America and Israel. The investment focus is on private companies developing novel drugs, medical devices and diagnostics for high- or even unmet medical needs. This is serving a market that is both driven by the pharmaceutical industry’s continued need for new products to supplement their ailing pipelines as well as by patient demand for safer and more efficacious treatments.

Forbion typically leads the investment syndicates it forms and has built a strong track record in recent years. Last year alone, they were involved in two of the three most successful exits of private, European life sciences companies, with the sale of Fovea Pharmaceuticals to Sanofi Aventis and the sale of PanGenetics to Abbott. As the venture industry is moving towards further specialization and consolidation, Forbion recently decided to expand its European footprint by opening an office in Munich and by hiring Dr. Holger Reithinger (formerly with Global Life Sciences Ventures and 3i) in April of this year.

FCF I Co-Invest Fund has already committed funds to five companies, including Circulite, Pathway Medical, AMT Holding, Biovex and Xention. Following the first close of FCF II investments have already been made in Niti, arGEN-X, Exosome, Promedior and Cardoz.

With these fundraisings, Forbion was able to further expand its global investor base of high quality limited partners, to include the EIF (also through their ERP-EIF and LfA-EIF facilities), US and EU pension funds, major insurance companies and leading European family offices.

Commenting on the close, Bart Bergstein, Managing Partner at Forbion said: “We are very pleased to have raised such a substantial amount as fundraising conditions have never been more challenging. Forbion’s long-running, successful track record in making life science investments, built over the past decade has been pivotal in our ability to raise this new capital. The fact that both existing limited partners decided to continue backing us and that many new investors decided to commit as well makes us very proud. Given that only few venture players have active funds to commit from, we currently see many highly attractive assets from an increasingly rich deal flow. We are therefore confident that both new funds could be at least as successful as FCF I.”

Juan Delgado-Moreira, Managing Director at Hamilton Lane (London, UK) and one of the longstanding investors in Forbion commented: “It is the Forbion team’s proven ability of applying commercial focus in investing in this technology-rich space that makes Forbion one of the strongest managers. We believe the European life sciences market to be very interesting if you are able to select the right funds.”

About Forbion Capital Partners

Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion’s investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.

For more information, please visit www.forbion.com.


CONTACT:

Media:
College Hill Life Sciences
Adam Michael/ Anastasios Koutsos
+44 (0)20 7866 7856
[email protected]
or
Forbion Capital Partners:
Bart Bergstein, Managing Partner
+31 35 699 30 10
[email protected]

 

KEYWORDS:   Europe  Netherlands  Germany

INDUSTRY KEYWORDS:   Health  Biotechnology  Professional Services  Finance

MEDIA:

Logo
 Logo
 

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.